Invivyd Stock Performance
| IVVD Stock | USD 0.79 0.02 2.47% |
On a scale of 0 to 100, Invivyd holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 5.09, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Invivyd will likely underperform. Please check Invivyd's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Invivyd's current trending patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Invivyd are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile basic indicators, Invivyd exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights IVVD ... | 05/15/2025 |
2 | Invivyd Announces Inclusion of PEMGARDA in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas | 05/23/2025 |
3 | Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA Clinical Trial Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID... | 05/27/2025 |
4 | Invivyd Price Target Reduced by H.C. Wainwright Amid Revenue Concerns IVVD Stock News | 05/28/2025 |
5 | Acquisition by Andersen Jill of 500000 shares of Invivyd subject to Rule 16b-3 | 05/30/2025 |
6 | Acquisition by Andersen Jill of 400000 shares of Invivyd at 3.59 subject to Rule 16b-3 | 06/10/2025 |
7 | Invivyd Announces Positive Full Phase 12 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventati... | 06/26/2025 |
8 | Invivyd and Leading Researchers Form SPEAR Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID andCOVID-19 Post-Vaccination Syndrome | 07/02/2025 |
9 | National Comprehensive Cancer Network Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer New Data Published in JAMA Oncolo... | 07/21/2025 |
10 | Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome | 07/23/2025 |
| Begin Period Cash Flow | 200.6 M | |
| Total Cashflows From Investing Activities | -140 K |
Invivyd Relative Risk vs. Return Landscape
If you would invest 66.00 in Invivyd on April 28, 2025 and sell it today you would earn a total of 13.00 from holding Invivyd or generate 19.7% return on investment over 90 days. Invivyd is currently generating 0.521% in daily expected returns and assumes 7.099% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Invivyd, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Invivyd Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Invivyd's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Invivyd, and traders can use it to determine the average amount a Invivyd's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0734
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IVVD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.1 actual daily | 63 63% of assets are less volatile |
Expected Return
| 0.52 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Invivyd is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Invivyd by adding it to a well-diversified portfolio.
Invivyd Fundamentals Growth
Invivyd Stock prices reflect investors' perceptions of the future prospects and financial health of Invivyd, and Invivyd fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Invivyd Stock performance.
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 46.99 M | ||||
| Shares Outstanding | 119.96 M | ||||
| Price To Book | 1.74 X | ||||
| Price To Sales | 2.57 X | ||||
| Revenue | 25.38 M | ||||
| Gross Profit | 34.24 M | ||||
| EBITDA | (173.76 M) | ||||
| Net Income | (169.93 M) | ||||
| Cash And Equivalents | 418.67 M | ||||
| Cash Per Share | 3.84 X | ||||
| Total Debt | 1.3 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.14 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (170.49 M) | ||||
| Earnings Per Share | (1.19) X | ||||
| Market Capitalization | 94.17 M | ||||
| Total Asset | 129.51 M | ||||
| Retained Earnings | (901.99 M) | ||||
| Working Capital | 38.7 M | ||||
About Invivyd Performance
By analyzing Invivyd's fundamental ratios, stakeholders can gain valuable insights into Invivyd's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Invivyd has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Invivyd has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (268.06) | (281.46) | |
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (2.62) | (2.49) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | (2.52) | (2.39) |
Things to note about Invivyd performance evaluation
Checking the ongoing alerts about Invivyd for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Invivyd help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Invivyd is way too risky over 90 days horizon | |
| Invivyd has some characteristics of a very speculative penny stock | |
| Invivyd appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 25.38 M. Net Loss for the year was (169.93 M) with profit before overhead, payroll, taxes, and interest of 34.24 M. | |
| Invivyd currently holds about 418.67 M in cash with (170.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Invivyd has a very weak financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome |
- Analyzing Invivyd's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Invivyd's stock is overvalued or undervalued compared to its peers.
- Examining Invivyd's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Invivyd's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Invivyd's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Invivyd's stock. These opinions can provide insight into Invivyd's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Invivyd Stock analysis
When running Invivyd's price analysis, check to measure Invivyd's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invivyd is operating at the current time. Most of Invivyd's value examination focuses on studying past and present price action to predict the probability of Invivyd's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invivyd's price. Additionally, you may evaluate how the addition of Invivyd to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |